HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the first quarter ended March 31, 2012. “AMPYRA continues to make unique and important contributions to the lives of people with MS. We were pleased to see consumer demand for AMPYRA increase progressively beginning in February, in response to our outreach programs,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We are excited about the potential for AMPYRA also to help patients with other neurological conditions, such as post-stroke deficits and cerebral palsy. We have accelerated the start of our proof-of-concept post-stroke deficit study, which we now expect to begin in the second quarter of 2012, and we expect initial results from our cerebral palsy study by the end of the year.”